Search clinical trials for: XNW4107

Total 6 results

Evopoint Biosciences Inc.

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

Bacterial Infections

United States
Evopoint Biosciences Inc.

Completed

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Bacterial Infections

United States
Evopoint Biosciences Inc.

Completed

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Bacterial Infections

United States
Evopoint Biosciences Inc.

Completed

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Bacterial Infections

United States
Evopoint Biosciences Inc.

Not yet recruiting

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Complicated Urinary Tract Infection Including Acute Pyelonephritis

United States
Evopoint Biosciences Inc.

Recruiting

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Recarbrio in Adults With HABP /VABP (REITAB-2)

Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

United States, Spain, France, Israel

3

Subscribe